Plans have been announced to form a new partnership between the government, Genomics England, UK Biobank, NHS England and Oxford Nanopore - a UK-headquartered, world-leading life sciences company. Oxford Nanopore uses long read sequencing technology to analyse genes and pathogens to rapidly diagnose a range of cancers, along with rare and infectious diseases. The technology can sequence long strands of DNA or RNA in one go, without breaking it up into smaller fragments.

In infectious diseases, Oxford Nanopore’s technology will help to create an early warning system for future pandemics and potential biological threats, both preventing disease and protecting the public. It will be used in the expansion of NHS England’s Respiratory Metagenomics programme, being led by Guy’s and St Thomas’ NHS Foundation Trust. It uses samples from patients with severe respiratory infections and rapid genetic testing to match those patients with the right treatments within 6 hours.

This novel and world-leading application, developed in partnership with the NHS, will allow potential outbreaks of bacterial or viral diseases to be monitored alongside antimicrobial resistance across the country. 

Following an initial successful pilot at St Thomas’ Hospital, the technology will now be rolled out from 10 to up to 30 NHS sites to address the current time lag between new pathogens emerging in the UK and action being taken to both treat affected patients and to prevent their spread, which will benefit people everywhere.

Health and Social Care Secretary Wes Streeting said: "If we fail to prepare, we should prepare to fail. Our NHS was already on its knees when the pandemic struck, and it was hit harder than any other comparable healthcare system. We cannot let history repeat itself. That’s why this historic partnership with Oxford Nanopore will ensure our world-leading scientists have the latest information on emerging threats at their fingertips. As we embrace the technological revolution, our 10 Year Health Plan will shift the NHS away from analogue to digital, saving countless more lives."

Science and Technology Secretary Peter Kyle said: "During the COVID-19 pandemic, we saw the power of the UK life sciences sector very clearly, from the Oxford-Astra Zeneca vaccine that saved so many lives, through to operating one of the world’s most effective COVID-19 surveillance systems, which spotted several emerging variants of the disease. This partnership will build on that expertise to monitor emerging diseases as they arise, putting our scientists and decision-makers one step ahead and providing the information they need to make informed decisions. Together with the ability to better diagnose cancers and rare diseases, we are leveraging UK life sciences to protect the public and ultimately save lives."

Professor Susan Hopkins, Chief Medical Advisor at the UK Health Security Agency, added: "Early detection is absolutely crucial in enabling us to respond effectively to any emerging pathogen. The UK already has a wealth of expertise in genomic surveillance, and this programme will build on that expertise and enable us to bring our resources and capability to tackle developing threats at greater speed. Enhancing the capacity for the NHS to determine new and emerging pathogens causing severe acute respiratory infections will improve the detection and emergence of infections. As part of the 100 days mission, this will enable the development of effective diagnostics for novel pathogens and enhance our pandemic preparedness."